Annual Inventory Summary of 2021 Updates to Popular Guidelines in the Field of Blood Disorders

In recent years, the research progress of various diseases in the field of hematology and tumors has continued.
Based on these research results, various guidelines at home and abroad have been expanded and revised
.

This article summarizes the 2021 consensus guidelines on popular guidelines in the field of blood diseases for readers' reference
.

Leukemia Leukemia is a kind of clonal malignant disease of hematopoietic stem cells and one of the most common hematological tumors
.

The 2021 guidelines have updated various aspects of leukemia-related diagnosis and treatment methods and medication recommendations
.

Especially in terms of acute myeloid leukemia, we are eagerly awaiting the "Chinese Guidelines for the Diagnosis and Treatment of Adult Acute Myeloid Leukemia (Non-Acute Promyelocytic Leukemia) (2021 Edition)" and the "Chinese Guidelines for the Diagnosis and Treatment of Relapsed and Refractory Acute Myeloid Leukemia ( 2021 Edition)" was finally updated
.

More details are as follows: 1.
2021 CSCO Guidelines Update | Leukemia Update Highlights 2.
Interpretation of Allogeneic Transplantation for Acute Leukemia and MDS Guidelines2021 CSCO Guidelines Conference 3.
2021 China AML Guidelines Update! After 4 years, finally waiting for you! 4.
New guidelines and new journeys: 2021 China AML diagnosis and treatment guidelines are released! 5.
Professor Huang Xiaojun: Looking at the development of AML treatment models from the release of the new guidelines in China 6.
Professor Jin Jie: From initial treatment to R/R, the new guidelines establish a new standard for the diagnosis and treatment of AML , The main manifestations are painless lymphadenopathy, hepatosplenomegaly, and all tissues and organs of the body can be involved.
According to tumor cells, it is divided into two types: non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL)
.

In 2021, a number of advances have been made in the field of lymphoma, and relevant guidelines have also been updated.
The details are as follows: 1.
The 2021 CSCO Lymphoma Diagnosis and Treatment Guidelines are updated, including velbutuximab.
2.
Prof.
Ma Jun| "Chinese Expert Consensus on Guiding Principles of Clinical Drug Use of Ortuzumab" helps standardize clinical drug use in China 3.
The NCCN Guidelines have been updated! 2021.
V1 version of peripheral T-cell lymphoma interpretation here Tumor immunotherapy guidelines 7.
Consensus overview | Chinese expert consensus on mobilization and collection of autologous hematopoietic stem cells for lymphoma (2020 edition) 8.
One article to understand the 2021 Chinese CMML diagnosis and treatment guidelines Multiple myeloma Multiple myeloma (MM) is a blood system A common malignant tumor, which occurs in middle-aged and elderly people, is the second most frequent hematological tumor after lymphoma
.

In recent years, the level of diagnosis and treatment of MM in China has made great progress, and it has gradually been in line with the international level.
The continuous emergence of new drugs has made the field of MM progress rapidly
.

Relevant guideline consensus has also been updated and summarized as follows: 1.
2021 CSCO Guideline Update | Multiple Myeloma Update Points 2.
Guideline Overview | China Multiple Myeloma Autologous Hematopoietic Stem Cell Transplant Guideline (2021 Edition) 3.
Updated! For relapsed and refractory MM, the IMWG treatment recommendation will be released in 2021, and you can learn quickly in five minutes.
4.
IMWG reminds you to read: the latest treatment recommendations for MM-related bone diseases.
Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up 6.
New Horizons in Myeloma | 2021 European Myeloma Network (EMN) Consensus Statement: Identification and Management of Smoldering Multiple Myeloma Immune Thrombocytopenia Immune Thrombocytopenia ( ITP) is a complex autoimmune disease characterized by thrombocytopenia due to accelerated platelet destruction and insufficient platelet production by megakaryocytes
.

The updated contents of the 2021 guideline consensus for adults and children are summarized as follows: 1.
Prof.
Hou Ming: Update points of "Chinese Guidelines for the Diagnosis and Treatment of Primary Immune Thrombocytopenia in Adults (2020 Edition)" 2.
Prof.
Peng Jun: Adults Updated Interpretation of Chinese Guidelines for Diagnosis and Treatment of ITP (2020 Edition)China Hematology Development Conference 3.
Prof.
Hu Qun | Keeping pace with the times and adapting measures to local conditions, the new version of the guidelines for Chinese children's ITP was released, and the standardized diagnosis and treatment of children's ITP further improved the blood of hemophilia Friend disease is an X-chromosome-linked recessive hereditary disease, which is caused by the lack of quantity or quality of coagulation factor VIII (FVIII)/IX (FIX) in plasma
.

Hemophilia A lacks FVIII and hemophilia B lacks FIX
.

In recent years, the field of hemophilia prevention and treatment has progressed rapidly.
It is worth noting that the "Guidelines for the Management of Hemophilia in China", edited by Professor Yang Renchi from the Hospital of Hematology, Chinese Academy of Medical Sciences, and several members of the editorial board of the China Hemophilia Collaborative Group (2021 Edition)" was born in response to demand
.

More information is as follows: 1.
Guideline overview | 2021 von Willebrand Diagnosis Guidelines 2.
Interview with Professor Yang Renchi | "China Hemophilia Management Guidelines (2021 Edition)" was released to help develop a new pattern of hemophilia diagnosis and treatment in China3 .
Finally waiting for you | The first "Chinese Expert Consensus on Pharmacokinetic Guidance for Hemophilia A Treatment" is released! (1) 4.
Finally waiting for you | The first "Chinese Expert Consensus on Pharmacokinetic Guidance of Hemophilia A Treatment" is released! (2) CAR-T cell therapy Chimeric antigen receptor-modified T cells (CAR-T) has become an important treatment for relapsed and refractory non-Hodgkin lymphoma (NHL)
.

With the deepening of research and the increase of clinical applications, clinicians have paid more and more attention to CAR-T cell-related side effects and clinical prevention and control measures
.

The Chinese Research Hospital Association Biotherapeutics Committee organized experts to refer to and draw on the existing consensus on CAR-T cytotoxicity management.
Expert Consensus on Clinical Management of Toxic and Side Effects of CAR-T Cell Therapy for NHL", which aims to provide more standardized treatment principles and exploratory treatment suggestions for clinicians to identify and deal with the toxic and side effects of CAR-T treatment of NHL
.

The details are as follows: 1.
CRS of CAR-T cytotoxic side effects | Expert consensus on clinical management of CAR-T cytotoxic side effects of NHL 2.
CAR-T cytotoxic side effects of CAR-T-related encephalopathy syndrome | CAR-T cell therapy of NHL toxicity Expert consensus on clinical management of side effects 3.
HLH/MAS of CAR-T cytotoxic side effects | Expert consensus on clinical management of CAR-T cytotoxic side effects in NHL 4.
Infection of CAR-T cytotoxic side effects | CAR-T cell therapy on NHL side effects Management Expert Consensus Anemia Anemia is a common sign in patients with hematological tumors, and its occurrence is caused by various reasons, including the tumor itself, the body's nutrient absorption disorder, or long-term treatment
.

The updated contents of the 2021 Compass Acupuncture Consensus on anemia are as follows: 1.
Interpretation of the 2021 CSCO Clinical Practice Guidelines for Tumor-Associated Anemia 2.
Gastrointestinal assessment of iron deficiency anemia, a list of the 7 recommendations of the AGA Guidelines | Guidelines Consensus 3.
Adults Management of Iron Deficiency Anemia: The British Society of Gastroenterology releases the latest guidelines | Consensus on other guidelines Click "read the original text", let's make progress together